125 related articles for article (PubMed ID: 2022663)
1. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
York JD; Li P; Gardell SJ
J Biol Chem; 1991 May; 266(13):8495-500. PubMed ID: 2022663
[TBL] [Abstract][Full Text] [Related]
2. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
3. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF; Bassel-Duby RS
Proc Natl Acad Sci U S A; 1990 May; 87(9):3530-3. PubMed ID: 2110366
[TBL] [Abstract][Full Text] [Related]
4. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
5. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D
J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996
[TBL] [Abstract][Full Text] [Related]
6. Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.
van Meijer M; Roelofs Y; Neels J; Horrevoets AJ; van Zonneveld AJ; Pannekoek H
J Biol Chem; 1996 Mar; 271(13):7423-8. PubMed ID: 8631768
[TBL] [Abstract][Full Text] [Related]
7. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
8. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
9. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
10. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
11. Mutational and immunochemical analysis of plasminogen activator inhibitor 1.
Shubeita HE; Cottey TL; Franke AE; Gerard RD
J Biol Chem; 1990 Oct; 265(30):18379-85. PubMed ID: 2120233
[TBL] [Abstract][Full Text] [Related]
12. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
[TBL] [Abstract][Full Text] [Related]
13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
14. Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1.
Tachias K; Madison EL
J Biol Chem; 1997 Jun; 272(23):14580-5. PubMed ID: 9169416
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
16. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
17. Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators.
Arndt A; Murphy P; Hart DA
Biochim Biophys Acta; 1992 Feb; 1138(2):149-56. PubMed ID: 1371701
[TBL] [Abstract][Full Text] [Related]
18. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system in human breast cancer.
Sumiyoshi K; Serizawa K; Urano T; Takada Y; Takada A; Baba S
Int J Cancer; 1992 Feb; 50(3):345-8. PubMed ID: 1735602
[TBL] [Abstract][Full Text] [Related]
20. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C.
Fay WP; Owen WG
Biochemistry; 1989 Jul; 28(14):5773-8. PubMed ID: 2505842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]